Octahydro fused azadecalin glucocorticoid receptor modulators
US-11370789-B2 · Jun 28, 2022 · US
Octahydro fused azadecalin glucocorticoid receptor modulators
US11560379B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11560379-B2 |
| Application number | US-202117146608-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 12, 2021 |
| Priority date | Nov 25, 2013 |
| Publication date | Jan 24, 2023 |
| Grant date | Jan 24, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
First claim
Opening claim text (preview).
What is claimed is: 1. The compound ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-4-yl)methanone, having the formula 2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the formula: 3. A method of modulating a glucocorticoid receptor, comprising contacting a glucocorticoid receptor with a compound having the formula:
Assignees
Inventors
Classifications
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Antineoplastic agents · CPC title
Ortho-condensed systems · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11560379B2 cover?
- The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
- Who is the assignee on this patent?
- Corcept Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).